These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9374514)

  • 21. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function.
    Flentke GR; Munoz E; Huber BT; Plaut AG; Kettner CA; Bachovchin WW
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1556-9. PubMed ID: 1671716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure and function of HIV-1 and SIV Tat proteins based on carboxy-terminal truncations, chimeric Tat constructs, and NMR modeling.
    Baier-Bitterlich G; Tretiakova A; Richardson MW; Khalili K; Jameson B; Rappaport J
    Biomed Pharmacother; 1998; 52(10):421-30. PubMed ID: 9921410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit alpha is crucial for their effects on proteasome function including antigen processing.
    Huang X; Seifert U; Salzmann U; Henklein P; Preissner R; Henke W; Sijts AJ; Kloetzel PM; Dubiel W
    J Mol Biol; 2002 Nov; 323(4):771-82. PubMed ID: 12419264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific binding of adenosine deaminase but not HIV-1 transactivator protein Tat to human CD26.
    Blanco J; Marié I; Callebaut C; Jacotot E; Krust B; Hovanessian AG
    Exp Cell Res; 1996 May; 225(1):102-11. PubMed ID: 8635502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amino acid modification in the HIV-1 Tat basic domain: insights from molecular dynamics and in vivo functional studies.
    Pantano S; Tyagi M; Giacca M; Carloni P
    J Mol Biol; 2002 May; 318(5):1331-9. PubMed ID: 12083521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and gamma interferon due to specific inhibition of dipeptidyl peptidase IV.
    Schön E; Demuth HU; Eichmann E; Horst HJ; Körner IJ; Kopp J; Mattern T; Neubert K; Noll F; Ulmer AJ
    Scand J Immunol; 1989 Feb; 29(2):127-32. PubMed ID: 2564215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities.
    Litovchick A; Lapidot A; Eisenstein M; Kalinkovich A; Borkow G
    Biochemistry; 2001 Dec; 40(51):15612-23. PubMed ID: 11747436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and dynamic properties of the HIV-1 tat transduction domain in the free and heparin-bound states.
    Hakansson S; Caffrey M
    Biochemistry; 2003 Aug; 42(30):8999-9006. PubMed ID: 12885232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mechanism and structural basis of interactions of dipeptidyl peptidase IV with adenosine deaminase and human immunodeficiency virus type-1 transcription transactivator.
    Fan H; Tansi FL; Weihofen WA; Böttcher C; Hu J; Martinez J; Saenger W; Reutter W
    Eur J Cell Biol; 2012 Apr; 91(4):265-73. PubMed ID: 21856036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication.
    Hwang S; Tamilarasu N; Kibler K; Cao H; Ali A; Ping YH; Jeang KT; Rana TM
    J Biol Chem; 2003 Oct; 278(40):39092-103. PubMed ID: 12857725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production.
    Reinhold D; Bank U; Bühling F; Neubert K; Mattern T; Ulmer AJ; Flad HD; Ansorge S
    Immunobiology; 1993 Aug; 188(4-5):403-14. PubMed ID: 7902330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication.
    Chen H; He J; Fong S; Wilcox G; Wood C
    J Virol; 2000 Mar; 74(6):2703-13. PubMed ID: 10684286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis.
    Campbell GR; Pasquier E; Watkins J; Bourgarel-Rey V; Peyrot V; Esquieu D; Barbier P; de Mareuil J; Braguer D; Kaleebu P; Yirrell DL; Loret EP
    J Biol Chem; 2004 Nov; 279(46):48197-204. PubMed ID: 15331610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.
    Hühn J; Olek S; Fleischer B; von Bonin A
    Cell Immunol; 1999 Feb; 192(1):33-40. PubMed ID: 10066344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of human dipeptidyl peptidase IV and human immunodeficiency virus type-1 transcription transactivator in Sf9 cells.
    Tansi FL; Blanchard V; Berger M; Tauber R; Reutter W; Fan H
    Virol J; 2010 Oct; 7():267. PubMed ID: 20942971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relating structure to function in the beta-propeller domain of dipeptidyl peptidase IV. Point mutations that influence adenosine deaminase binding, antibody binding and enzyme activity.
    Gorrell MD; Abbott CA; Kähne T; Levy MT; Church WB; McCaughan GW
    Adv Exp Med Biol; 2000; 477():89-95. PubMed ID: 10849733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain.
    Ariumi Y; Kaida A; Hatanaka M; Shimotohno K
    Biochem Biophys Res Commun; 2001 Sep; 287(2):556-61. PubMed ID: 11554765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes.
    Schön E; Born I; Demuth HU; Faust J; Neubert K; Steinmetzer T; Barth A; Ansorge S
    Biol Chem Hoppe Seyler; 1991 May; 372(5):305-11. PubMed ID: 1678607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional analysis of the N-terminal domain of Tat protein of the human immunodeficiency virus type 1.
    Reddy MV; Desai M; Jeyapaul J; Prasad DD; Seshamma T; Palmeri D; Khan SA
    Oncogene; 1992 Sep; 7(9):1743-8. PubMed ID: 1501886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An autocrine loop of HIV type-1 Tat protein responsible for the improved survival/proliferation capacity of permanently Tat-transfected cells and required for optimal HIV-1 LTR transactivating activity.
    Zauli G; La Placa M; Vignoli M; Re MC; Gibellini D; Furlini G; Milani D; Marchisio M; Mazzoni M; Capitani S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Nov; 10(3):306-16. PubMed ID: 7552492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.